teloxantrone

structure given in first source

Also Known As:

CI 937; CI-937; Dup 937; Dup-937; teloxantrone hydrochloride; Anthra(1,9-cd)pyrazol-6(2H)-one, 7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-

Networked: 7 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 05/01/1993 - "Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. "
2.	Melanoma (Melanoma, Malignant) 09/01/1993 - "A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG)."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/01/1993 - "A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. "
4.	Cardiotoxicity 10/01/1989 - "The novel anthrapyrazole agent, CI-937, which has shown exceptional in vivo anticancer activity and reduced cardiotoxicity in preclinical models has been developed at the Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co. "
5.	Neutropenia 12/01/1991 - "We conclude that the dose-limiting toxicity of CI-937 is neutropenia and that the recommended phase II starting dose is 22 mg/m2."

Related Drugs and Biologics

1.	teloxantrone
2.	anthrapyrazole
3.	Doxorubicin (Adriamycin)
4.	losoxantrone